AbCellera Biologics Inc. (ABCL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 233 | 375 | 485 | 38 | 29 | 75 | 66 | 27 |
| Operating profit | $m | -217 | -225 | ||||||
| Net profit | $m | 119 | 153 | 159 | -146 | -163 | -146 | -165 | -193 |
| EPS reported | $ | -0.49 | -0.54 | ||||||
| Operating cashflow per share | $ | -0.44 | -0.51 | ||||||
| Capex per share | $ | 0.14 | 0.08 | ||||||
| FCF per share | $ | -0.58 | -0.59 | ||||||
| Free cash flow | $m | -174 | -179 | ||||||
| Net debt | $m | -534 | -534 | ||||||
| Book value equity | $m | 967 | 896 | ||||||
| Book value per share | $ | 3.24 | 2.93 | ||||||
| Number of shares | m | 298.71 | 305.56 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.06 | 1.14 | ||||||
| P/S LTM | x | 13.60 | 15.44 | ||||||
| P/FCF LTM | x | -5.87 | -5.69 | ||||||
| EV/EBITDA LTM | x | -6.97 | -6.46 | ||||||
| EV/Sales LTM | x | 13.79 | 52.98 | ||||||
| Earnings Yield LTM | % | -14.33% | -4.71% | ||||||
| FCF Yield | % | -17.04% | -17.57% | ||||||
| Quality | |||||||||
| ROE | % | -15.14% | -17.49% | ||||||
| ROIC | % | -13.78% | -14.95% | ||||||
| Operating margin | % | -2.89% | -3.40% | ||||||
| Gross margin | % | +61.64% | +74.95% | ||||||
| FCF/Sales | % | -231.69% | -271.19% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +160.56% | +129.50% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.22 | -1.32 | ||||||
| Net Debt/EBITDA | x | -0.10 | -0.10 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.55 | -0.60 | ||||||
| Gross debt/equity | x | 0.15 | 0.15 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free